Part-Time
Establishment Secretary
Updated on 8/24/2026
Cencora
10,001+ employees
Global pharmaceutical distribution and services provider
No salary listed
Nice, France
In Person
Bachelor's
 People & HR (2) |
|---|
| , |
Get referred to Cencora
See people who can refer or advise you
- A Bac to Bac+2 education.
- Initial experience in a similar position, particularly with time and payroll management.
- Proficiency with office tools, including Microsoft Office.
- A rigorous, organized, dynamic, service-oriented, and team-focused working style.
- Manage site personnel administration in coordination with headquarters, including employee hours, sick leave, workplace accidents, temporary-worker contracts, and related tracking.
- Support the establishment director with site social matters, including social meetings, elections, delegation tracking, medical visits, and employee files.
- Act as the employees' primary contact for social-related questions and participate in local company communications.
- Manage the establishment's secretariat, including telephone and in-person reception, mail, consumables purchasing, and administrative file processing.
- Handle ordinary commercial relations with customers, including customer start-up forms, financial files, customer statements, commercial documents, and related administrative tasks.
- Manage customer complaints by contacting customers, researching and resolving issues, and tracking indicators to support customer satisfaction.
Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.
Company Size
10,001+
Company Stage
IPO
Headquarters
Pennsylvania
Founded
1907
Get referred to Cencora
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 5, 2026: Cencora raised fiscal 2026 EPS guidance to $17.75-$17.95.
- July 31, 2026: Cencora expanded its revolver to $7 billion, extending maturity to 2031.
- Cencora completed $1 billion in share repurchases during Q3, reducing diluted shares to 194 million.
What critics are saying
- Baltimore dropped its opioid case after Maryland's April 2026 ruling vacated Cencora's $152 million verdict.
- Cencora directors still face a $111.3 million opioid settlement, confirming persistent litigation over legacy conduct.
- A California labor class action and heavy debt coverage pressure threaten margins before fiscal 2027.
What makes Cencora unique
- Cencora's specialty platform, including OneOncology and RCA MSOs, drives outsized growth on August 5, 2026.
- Nucleus inventory tools embed Cencora inside specialty physician practices' workflows across 20+ sites.
- Global distribution plus World Courier and European 3PL give Cencora reach beyond U.S. drug flow.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Parental Leave
Adoption Assistance
Infertility Coverage
Family Planning Benefits
Behavioral Health Solutions
Professional Development Budget
Training Programs
Company News
Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.
Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.
Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.
Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.
CVS Health led health insurance providers in Q1, with revenues of $100.4 billion, up 6.2% year on year and beating analyst expectations by 6.3%. The company exceeded full-year EPS guidance estimates. The 12 health insurance provider stocks tracked reported strong Q1 results overall. Revenues beat consensus estimates by 1.4%, whilst next quarter's guidance was in line. Share prices rose 37.4% on average following the earnings announcements. Cencora performed weakest amongst peers, reporting revenues of $78.36 billion, up 3.8% year on year. This fell short of analyst expectations by 3.9%. The stock has remained flat since reporting and currently trades at $303.53. The industry faces tailwinds from an ageing population and improved data analytics, but regulatory scrutiny on pricing and medical cost inflation may impact margins.